{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T09:28:50Z","timestamp":1794216530557,"version":"4.8.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000261","name":"MS Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jneuroim.2026.579083","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:44:39Z","timestamp":1788565479000},"page":"579083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Disease-modifying therapy uptake in a pediatric-onset multiple sclerosis population, British Columbia, Canada"],"prefix":"10.1016","volume":"421","author":[{"given":"Colin","family":"Wilbur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinshan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Tremlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jneuroim.2026.579083_bb0005","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/jamaneurol.2023.5566","article-title":"Highly effective therapies as first-line treatment for pediatric-onset multiple sclerosis","volume":"81","author":"Benallegue","year":"2024","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.jneuroim.2026.579083_bb0010","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1056\/NEJMoa1800149","article-title":"Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis","volume":"379","author":"Chitnis","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2026.579083_bb0015","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.msard.2016.05.006","article-title":"Adherence and persistence to drug therapies for multiple sclerosis: a population-based study","volume":"8","author":"Evans","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.jneuroim.2026.579083_bb0020","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1001\/jamaneurol.2023.2125","article-title":"Initiation patterns of disease-modifying therapies for multiple sclerosis among US adults and children, 2001 through 2020","volume":"80","author":"Henderson","year":"2023","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579083_bb0025","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25737","article-title":"Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis","volume":"88","author":"Krysko","year":"2020","journal-title":"Ann. Neurol."},{"issue":"17","key":"10.1016\/j.jneuroim.2026.579083_bb0030","doi-asserted-by":"crossref","first-page":"e1579","DOI":"10.1212\/WNL.0000000000006395","article-title":"Incidence and prevalence of MS in children: a population-based study in Ontario, Canada","volume":"91","author":"Marrie","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jneuroim.2026.579083_bb0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14737175.2021.1847085","article-title":"Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting","volume":"21","author":"Ng","year":"2021","journal-title":"Expert. Rev. Neurother."},{"issue":"4","key":"10.1016\/j.jneuroim.2026.579083_bb0040","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/17512433.2025.2481868","article-title":"Scoping review of the availability and uptake of disease modifying therapies in children and adolescents with multiple sclerosis","volume":"18","author":"Strasser","year":"2025","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.jneuroim.2026.579083_bb0045","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/08830738231176588","article-title":"Trends in the epidemiology and treatment of pediatric-onset multiple sclerosis in Alberta, Canada","volume":"38","author":"Yearwood","year":"2023","journal-title":"J. Child Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2026.579083_bb0050","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archneurol.2010.325","article-title":"Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis","volume":"68","author":"Yeh","year":"2011","journal-title":"Arch. Neurol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826002328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826002328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T09:18:16Z","timestamp":1794215896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572826002328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":10,"alternative-id":["S0165572826002328"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.579083","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease-modifying therapy uptake in a pediatric-onset multiple sclerosis population, British Columbia, Canada","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.579083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"579083"}}